Quest Diagnostics Beats Q1 Estimates with $2.50 EPS, Raises Full-Year Guidance
Quest Diagnostics (NYSE: DGX) delivered stronger-than-expected first quarter results, with adjusted earnings per share of $2.50 representing a 13.1% increase from the prior year's $2.21. The diagnostic testing leader raised its full-year guidance on the back of robust organic growth and continued execution of its strategic initiatives.
Key Numbers
The numbers tell a compelling growth story for Quest Diagnostics in the first quarter of 2026. Revenue surged 9.2% year-over-year to $2.90 billion, with organic revenue growth accounting for 9.0% of that increase — indicating the company is gaining market share through its core operations rather than acquisitions.
Reported diluted EPS climbed 15.5% to $2.24, while adjusted diluted EPS of $2.50 beat analyst expectations and grew 13.1% from the prior year's $2.21. The strong earnings performance was driven by both revenue growth and margin expansion, with adjusted operating income margin improving slightly to 15.4% from 15.3% a year ago.
Perhaps most impressive was the 10.9% increase in requisition volume, with organic requisition volume up 10.8%. This volume growth more than offset a 1.3% decline in revenue per requisition, suggesting Quest is successfully capturing market share even as pricing faces some pressure. The Diagnostic Information Services segment, which represents the bulk of Quest's business, saw revenues increase 9.4% to $2.83 billion.
Operating income jumped 15.5% to $399 million on a reported basis, while adjusted operating income rose 10.0% to $447 million. Net income attributable to Quest increased 14.4% to $252 million, demonstrating strong operational leverage as revenue growth translated efficiently to the bottom line.
What Management Said
CEO Jim Davis struck an optimistic tone in discussing the quarter's results, emphasizing that the company's growth was "almost entirely organic" — a key indicator of underlying business health. Davis attributed the strong performance to "disciplined execution of our strategy to deliver innovative diagnostic solutions for our customers' evolving needs."
Management's confidence was clearly reflected in the raised guidance for 2026. The company now expects full-year revenues between $11.78 billion and $11.90 billion, up from the previous range of $11.70 billion to $11.82 billion. This represents growth of 6.8% to 7.8% for the full year.
More importantly for shareholders, Quest raised its EPS outlook across the board. Reported diluted EPS is now expected to be between $9.58 and $9.78, up from the prior range of $9.45 to $9.65. Adjusted diluted EPS guidance was increased to $10.63 to $10.83, compared to the previous $10.50 to $10.70 range.
The company highlighted several strategic wins during the quarter, including the implementation of its Co-Lab Solutions joint venture with Corewell Health in Michigan and expansion of its lab testing services beyond Fresenius Medical Care's dialysis clinics to other providers. Management also touted double-digit revenue growth in Advanced Diagnostics, particularly for its Quest AD-Detect blood tests for Alzheimer's disease.
On the innovation front, Quest revealed that its new AI Companion tool — designed to help patients better understand their lab test reports — has already been used approximately 350,000 times since rolling out earlier in the quarter. This demonstrates the company's commitment to improving the patient experience while leveraging technology to differentiate its services.
What to Watch
Looking ahead, investors should monitor several key initiatives that could drive future growth. Project Nova, Quest's multi-year transformation of its order-to-cash processes and systems, represents a significant operational investment with the first wave of solutions planned for fall 2027. Success here could improve margins and operational efficiency.
The consumer health channel continues to show robust growth through Quest's questhealth.com platform and partnerships with consumer health companies. As more consumers take charge of their health decisions, this direct-to-consumer segment could become an increasingly important growth driver.
Quest's Advanced Diagnostics portfolio, particularly in Alzheimer's testing and cardiometabolic disease, represents a higher-margin opportunity as the company moves beyond routine testing into more specialized areas. The research collaboration with City of Hope to study cancer monitoring using Haystack MRD could open new markets in oncology diagnostics.
One area of slight concern is cash flow, with operating cash flow declining 11.6% to $278 million despite the strong earnings growth. This appears to be timing-related due to working capital changes, particularly the $180 million increase in accounts receivable. The company maintained its full-year cash flow guidance at approximately $1.75 billion, suggesting management isn't concerned about the quarterly variation.
The competitive landscape remains intense in diagnostic testing, with both traditional competitors and new entrants vying for market share. Quest's ability to maintain its 10.8% organic volume growth while managing pricing pressure will be critical. The 1.3% decline in revenue per requisition bears watching, though it was more than offset by volume gains this quarter.
With the raised guidance implying continued strength through 2026, Quest Diagnostics appears well-positioned to capitalize on growing demand for diagnostic testing services. The combination of organic growth, margin improvement, and strategic investments in technology and partnerships suggests the company is successfully navigating the evolving healthcare landscape while delivering value to shareholders.
*StockCliff Research*